Cobenfy, a brand new drug made by Bristol Myers Squibb and authorised by the FDA final week, triggers muscarinic receptors as a substitute of dopamine receptors. It is the primary schizophrenia remedy to take action.
Bristol Myers Squibb
conceal caption
toggle caption
Bristol Myers Squibb
Cobenfy, a brand new drug made by Bristol Myers Squibb and authorised by the FDA final week, triggers muscarinic receptors as a substitute of dopamine receptors. It is the primary schizophrenia remedy to take action.
Bristol Myers Squibb
For the previous 70 years, schizophrenia therapies all focused the identical chemical: dopamine. Whereas that works for some, it causes brutal unwanted side effects for others.
An antipsychotic drug authorised final month by the FDA adjustments that. It triggers muscarinic receptors as a substitute of dopamine receptors. The drug is the results of an opportunity scientific discovering … from a examine that wasn’t even targeted on schizophrenia.
This episode, host Emily Kwong and NPR pharmaceutical correspondent Sydney Lupkin dive into the place the drug originated, the way it works and what it would shift for individuals with schizophrenia.
Learn extra of Sydney’s reporting on this new remedy.
This episode was produced by Hannah Chinn and edited by our showrunner, Rebecca Ramirez. The information have been checked by Tyler Jones. The audio engineer was Maggie Luthar.
Hearken to Brief Wave on Spotify and Apple Podcasts.
Pay attention to each episode of Brief Wave sponsor-free and assist our work at NPR by signing up for Brief Wave+ at plus.npr.org/shortwave.
This episode was produced by Hannah Chinn and edited by Rebecca Ramirez. It was fact-checked by Tyler Jones. Maggie Luthar was the audio engineer.
